Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study
DOI:
https://doi.org/10.2340/1651-226X.2024.34802Keywords:
Cohort study, Denmark, Epidemiology, malignant pleural mesothelioma, registriesAbstract
Background: Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with poor prognosis and limited treatment options. Immunotherapy shows potential for improved outcomes; however, real-world evidence on its use will take time to accumulate. This study examined patient characteristics, treatment patterns, overall survival (OS), and predictors of mortality among patients diagnosed with MPM in Denmark prior to the introduction of newer treatments.
Methods: This historical cohort study based on routinely collected Danish National Registry data included adults newly diagnosed with MPM between 01 January 2011 and 31 May 2018. Summary statistics were used to describe patient characteristics and initial treatment. OS was estimated using Kaplan-Meier methods; Cox regression was used to compare patient mortality against the (age/sex-matched) general population and to investigate mortality predictors.
Results: Overall, 880 patients were included; 44% had advanced MPM, 37% had non-advanced MPM, and 19% had unknown MPM stage. Median age at diagnosis was 71.9 years, and 82% of the patients were male. Within 180 days of diagnosis, no treatment was recorded for 215 patients (54%) with advanced MPM and 150 (46%) with non-advanced MPM. Median time-to-initial treatment (interquartile range) was 47 days (31–111) overall, 40 days (28–77) in patients with advanced MPM, and 53 days (35–121) with non-advanced MPM. Median OS was 13.7 months overall (non-advanced MPM: 18.0 months vs. advanced MPM: 10.0 months). Predictors of higher mortality were older age at diagnosis, histology, and advanced MPM stage.
Interpretation: These findings provide a baseline upon which to evaluate MPM epidemiology as newer treatments are adopted in routine practice.
Downloads
References
Tedesco J, Jaradeh M, Vigneswaran WT. Malignant pleural mesothelioma: current understanding of the immune microenvironment and treatments of a rare disease. Cancers (Basel). 2022;14(18):4415.
https://doi.org/10.3390/cancers14184415 DOI: https://doi.org/10.3390/cancers14184415
Zhai Z, Ruan J, Zheng Y, Xiang D, Li N, Hu J et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Netw Open. 2021;4(8):e2120360.
https://doi.org/10.1001/jamanetworkopen.2021.20360 DOI: https://doi.org/10.1001/jamanetworkopen.2021.20360
Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v31–v39.
https://doi.org/10.1093/annonc/mdv199 DOI: https://doi.org/10.1093/annonc/mdv199
Hemminki K, Forsti A, Chen T, Hemminki A. Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden. BMC Cancer. 2021;21(1):1189.
https://doi.org/10.1186/s12885-021-08913-2 DOI: https://doi.org/10.1186/s12885-021-08913-2
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953.
https://doi.org/10.1183/13993003.00953-2019 DOI: https://doi.org/10.1183/13993003.00953-2019
Reid A, de Klerk NH, Magnani C, Ferrante D, Berry G, Musk AW et al. Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax. 2014;69(9):843–850.
https://doi.org/10.1136/thoraxjnl-2013-204161 DOI: https://doi.org/10.1136/thoraxjnl-2013-204161
Fonseca AS, Jorgensen AK, Larsen BX, Moser-Johansen M, Flachs EM, Ebbehoj NE et al. Historical asbestos measurements in Denmark-a national database. Int J Environ Res Public Health. 2022;19(2):643.
https://doi.org/10.3390/ijerph19020643 DOI: https://doi.org/10.3390/ijerph19020643
Mensi C, De Matteis S, Dallari B, Riboldi L, Bertazzi PA, Consonni D. Incidence of mesothelioma in Lombardy, Italy: exposure to asbestos, time patterns and future projections. Occup Environ Med. 2016;73(9):607–613.
https://doi.org/10.1136/oemed-2016-103652 DOI: https://doi.org/10.1136/oemed-2016-103652
Loomis D, Richardson DB, Elliott L. Quantitative relationships of exposure to chrysotile asbestos and mesothelioma mortality. Am J Ind Med. 2019;62(6):471–477.
https://doi.org/10.1002/ajim.22985 DOI: https://doi.org/10.1002/ajim.22985
Brims F. Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers (Basel). 2021;13(16):4194.
https://doi.org/10.3390/cancers13164194 DOI: https://doi.org/10.3390/cancers13164194
Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C et al. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res. 2018;7:1184.
https://doi.org/10.12688/f1000research.15512.2 DOI: https://doi.org/10.12688/f1000research.15512.2
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472–486.
https://doi.org/10.1183/16000617.0063-2016 DOI: https://doi.org/10.1183/16000617.0063-2016
American Cancer Society. Survival rates for malignant mesothelioma. [cited 2022 Nov 14]. Available from: https://www.cancer.org/cancer/malignant-mesothelioma/detection-diagnosis-staging/survival-statistics.html
Offin M, Rusch VW, Rimner A, Adusumilli PS, Zauderer MG. Evolving landscape of initial treatments for patients with malignant pleural mesotheliomas: clinical trials to clinical practice. Oncologist. 2022;27(8):610–614.
https://doi.org/10.1093/oncolo/oyac113 DOI: https://doi.org/10.1093/oncolo/oyac113
Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D et al. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631–1639.
https://doi.org/10.1097/JTO.0b013e31826915f1 DOI: https://doi.org/10.1097/JTO.0b013e31826915f1
Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D’Amico TA et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23–32.
https://doi.org/10.1016/j.jss.2015.01.043 DOI: https://doi.org/10.1016/j.jss.2015.01.043
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644.
https://doi.org/10.1200/JCO.2003.11.136 DOI: https://doi.org/10.1200/JCO.2003.11.136
Nowak AK, Jackson A, Sidhu C. Management of advanced pleural mesothelioma-at the crossroads. JCO Oncol Pract. 2022;18(2):116–124.
https://doi.org/10.1200/OP.21.00426 DOI: https://doi.org/10.1200/OP.21.00426
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386.
https://doi.org/10.1016/S0140-6736(20)32714-8 DOI: https://doi.org/10.1016/S0140-6736(20)32714-8
Bristol Myers Squibb. Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) as first-line treatment for unresectable malignant pleural mesothelioma. 2021 [cited 2022 Nov 23]. Available from: https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Unresectable-Malignant-Pleural-Mesothelioma/default.aspx
Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446–451.
https://doi.org/10.1158/1078-0432.CCR-21-1466 DOI: https://doi.org/10.1158/1078-0432.CCR-21-1466
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(2):129–142.
https://doi.org/10.1016/j.annonc.2021.11.005 DOI: https://doi.org/10.1016/j.annonc.2021.11.005
Medicinraadet. Medicinraadet 2022. [cited 2023 May 17]. Available from: https://medicinraadet.dk/anbefalinger-og-vejledninger/laegemidler-og-indikationsudvidelser/m-p/nivolumab-opdivo-i-komb-med-ipilimumab-til-1-linjebehandling-af-ikke-resekterbar-malignt-pleuralt-mesotheliom
Baas P, Daumont MJ, Lacoin L, Penrod JR, Carroll R, Venkatesan S et al. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: a nationwide CAS registry analysis from the I-O Optimise initiative. Lung Cancer. 2021;162:185–193.
https://doi.org/10.1016/j.lungcan.2021.11.001 DOI: https://doi.org/10.1016/j.lungcan.2021.11.001
Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A et al. Nordic health registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533–554.
https://doi.org/10.2147/CLEP.S314959 DOI: https://doi.org/10.2147/CLEP.S314959
Ekman S, Griesinger F, Baas P, Chao D, Chouaid C, O’Donnell JC et al. I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. Future Oncol. 2019;15(14):1551–1563.
https://doi.org/10.2217/fon-2019-0025 DOI: https://doi.org/10.2217/fon-2019-0025
Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549.
https://doi.org/10.1007/s10654-014-9930-3 DOI: https://doi.org/10.1007/s10654-014-9930-3
Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(7 Suppl):42–45. DOI: https://doi.org/10.1177/1403494810393562
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
https://doi.org/10.2147/CLEP.S91125 DOI: https://doi.org/10.2147/CLEP.S91125
Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543–549.
https://doi.org/10.21037/tlcr.2018.07.05 DOI: https://doi.org/10.21037/tlcr.2018.07.05
Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 1996;14(1):1–12.
https://doi.org/10.1016/0169-5002(95)00508-0 DOI: https://doi.org/10.1016/0169-5002(95)00508-0
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
https://doi.org/10.1080/01621459.1958.10501452 DOI: https://doi.org/10.1080/01621459.1958.10501452
Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220.
https://doi.org/10.1111/j.2517-6161.1972.tb00899.x DOI: https://doi.org/10.1111/j.2517-6161.1972.tb00899.x
Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. Lung Cancer. 2015;89(2):212–217.
https://doi.org/10.1016/j.lungcan.2015.05.014 DOI: https://doi.org/10.1016/j.lungcan.2015.05.014
Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21(st) century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28–S38.
https://doi.org/10.21037/tlcr.2019.11.11 DOI: https://doi.org/10.21037/tlcr.2019.11.11
Brcic L, Kern I. Clinical significance of histologic subtyping of malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9(3):924–933.
https://doi.org/10.21037/tlcr.2020.03.38 DOI: https://doi.org/10.21037/tlcr.2020.03.38
Ziolkowska B, Cybulska-Stopa B, Papantoniou D, Suwinski R. Systemic treatment in patients with malignant pleural mesothelioma – real life experience. BMC Cancer. 2022;22(1):432.
https://doi.org/10.1186/s12885-022-09490-8 DOI: https://doi.org/10.1186/s12885-022-09490-8
Kuryk L, Rodella G, Staniszewska M, Pancer KW, Wieczorek M, Salmaso S et al. Novel insights into mesothelioma therapy: emerging avenues and future prospects. Front Oncol. 2022;12:916839.
https://doi.org/10.3389/fonc.2022.916839 DOI: https://doi.org/10.3389/fonc.2022.916839
Skammeritz E, Omland O, Hansen J, Johansen JP. Regional differences in incidence of malignant mesothelioma in Denmark. Dan Med J. 2013;60(3):A4592.
Rijavec E, Biello F, Barletta G, Dellepiane C, Genova C. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (review). Mol Clin Oncol. 2022;16(4):89.
https://doi.org/10.3892/mco.2022.2522 DOI: https://doi.org/10.3892/mco.2022.2522
Davis AP, Kao SC, Clarke SJ, Boyer M, Pavlakis N. Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opin Emerg Drugs. 2021;26(2):179–192.
https://doi.org/10.1080/14728214.2021.1924670 DOI: https://doi.org/10.1080/14728214.2021.1924670
Lapidot M, Saladi SV, Salgia R, Sattler M. Novel therapeutic targets and immune dysfunction in malignant pleural mesothelioma. Front Pharmacol. 2021;12:806570.
https://doi.org/10.3389/fphar.2021.806570 DOI: https://doi.org/10.3389/fphar.2021.806570
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Jens Benn Sørensen, Paul Baas, Szimonetta Komjáthiné Szépligeti, Alma B. Pedersen, Søren P. Johnsen, Robert Carroll, Minouk J. Schoemaker, Caroline Rault, Melinda J. Daumont, Vera Ehrenstein
This work is licensed under a Creative Commons Attribution 4.0 International License.
